StockData
Puma Biotechnology, Inc. logo

Puma Biotechnology, Inc. (PBYI) stock

PBYINasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 14/3019% below fair value
$7.22+0.08 (+1.12%)

Close on Nov 18, 2026Market cap $372.70MP/E 13.9Yield –

Puma Biotechnology cash

Cash and short-term investments held at the end of each period.

Puma Biotechnology's cash was $86.80M at Jun 30, 2026. For fiscal 2025 it was $91.63M, up 5.5% from the year before. Over ten years it grew -8.2% a year on average. The highest annual figure on record is $229.40M in fiscal 2016.

Annual cash

PeriodPeriod endValueChange
FY2025Dec 31, 2025$91.63M+5.5%
FY2024Dec 31, 2024$86.84M+77.5%
FY2023Dec 31, 2023$48.92M+5.1%
FY2022Dec 31, 2022$46.55M-33.4%
FY2021Dec 31, 2021$69.85M-12.5%
FY2020Dec 31, 2020$79.81M-28.5%
FY2019Dec 31, 2019$111.64M-32.5%
FY2018Dec 31, 2018$165.42M+102.5%
FY2017Dec 31, 2017$81.70M-64.4%
FY2016Dec 31, 2016$229.40M+6.3%
FY2015Dec 31, 2015$215.89M+52.8%
FY2014Dec 31, 2014$141.33M+68.4%
FY2013Dec 31, 2013$83.95M-38.9%
FY2012Dec 31, 2012$137.41M+157.4%
FY2011Dec 31, 2011$53.38M–
FY2010Dec 31, 2010$0-100.0%
FY2009Dec 31, 2009$2.41K–

Quarterly cash

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$86.80M-2.2%
Q1 FY2026Mar 31, 2026$91.66M+11.6%
Q4 FY2025Dec 31, 2025$91.63M+5.5%
Q3 FY2025Sep 30, 2025$88.43M-1.6%
Q2 FY2025Jun 30, 2025$88.74M-0.1%
Q1 FY2025Mar 31, 2025$82.12M+2.9%
Q4 FY2024Dec 31, 2024$86.84M+77.5%
Q3 FY2024Sep 30, 2024$89.91M+86.3%
Q2 FY2024Jun 30, 2024$88.79M+86.3%
Q1 FY2024Mar 31, 2024$79.82M+69.6%
Q4 FY2023Dec 31, 2023$48.92M+5.1%
Q3 FY2023Sep 30, 2023$48.27M+4.6%
Q2 FY2023Jun 30, 2023$47.65M+3.8%
Q1 FY2023Mar 31, 2023$47.07M+2.6%
Q4 FY2022Dec 31, 2022$46.55M-33.4%
Q3 FY2022Sep 30, 2022$46.14M-33.9%
Q2 FY2022Jun 30, 2022$45.92M-57.9%
Q1 FY2022Mar 31, 2022$45.86M-57.9%
Q4 FY2021Dec 31, 2021$69.85M-12.5%
Q3 FY2021Sep 30, 2021$69.84M-35.9%
Q2 FY2021Jun 30, 2021$108.98M+1.6%
Q1 FY2021Mar 31, 2021$109.05M+8.4%
Q4 FY2020Dec 31, 2020$79.81M-28.5%
Q3 FY2020Sep 30, 2020$109.02M-1.3%
Q2 FY2020Jun 30, 2020$107.27M-8.8%
Q1 FY2020Mar 31, 2020$100.56M-33.1%
Q4 FY2019Dec 31, 2019$111.64M-32.5%
Q3 FY2019Sep 30, 2019$110.44M-13.7%
Q2 FY2019Jun 30, 2019$117.67M-12.5%
Q1 FY2019Mar 31, 2019$150.40M+91.5%
Q4 FY2018Dec 31, 2018$165.42M+102.5%
Q3 FY2018Sep 30, 2018$127.95M+20.4%
Q2 FY2018Jun 30, 2018$134.51M-11.3%
Q1 FY2018Mar 31, 2018$78.55M-59.5%
Q4 FY2017Dec 31, 2017$81.70M-64.4%
Q3 FY2017Sep 30, 2017$106.30M-2.4%
Q2 FY2017Jun 30, 2017$151.60M–
Q1 FY2017Mar 31, 2017$194.00M–
Q4 FY2016Dec 31, 2016$229.40M–
Q3 FY2016Sep 30, 2016$108.93M–

More Puma Biotechnology figures

See a number that looks wrong?